GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dova Pharmaceuticals Inc (NAS:DOVA) » Definitions » Cost of Goods Sold

Dova Pharmaceuticals (Dova Pharmaceuticals) Cost of Goods Sold : $1.90 Mil (TTM As of Sep. 2019)


View and export this data going back to 2017. Start your Free Trial

What is Dova Pharmaceuticals Cost of Goods Sold?

Dova Pharmaceuticals's cost of goods sold for the three months ended in Sep. 2019 was $0.65 Mil. Its cost of goods sold for the trailing twelve months (TTM) ended in Sep. 2019 was $1.90 Mil.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Dova Pharmaceuticals's Gross Margin % for the three months ended in Sep. 2019 was 80.64%.

Cost of Goods Sold is also directly linked to Inventory Turnover. Dova Pharmaceuticals's Inventory Turnover for the three months ended in Sep. 2019 was 0.15.


Dova Pharmaceuticals Cost of Goods Sold Historical Data

The historical data trend for Dova Pharmaceuticals's Cost of Goods Sold can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dova Pharmaceuticals Cost of Goods Sold Chart

Dova Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18
Cost of Goods Sold
- - 1.18

Dova Pharmaceuticals Quarterly Data
Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Cost of Goods Sold Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.37 0.29 0.52 0.44 0.65

Dova Pharmaceuticals Cost of Goods Sold Calculation

Cost of Goods Sold is the aggregate cost of goods produced and sold, and services rendered during the reporting period. It excludes Total Operating Expense, such as Depreciation, Depletion and Amortization and Selling, General, & Admin. Expense.

Cost of Goods Sold for the trailing twelve months (TTM) ended in Sep. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.90 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Dova Pharmaceuticals  (NAS:DOVA) Cost of Goods Sold Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Dova Pharmaceuticals's Gross Margin % for the three months ended in Sep. 2019 is calculated as:

Gross Margin %=(Revenue - Cost of Goods Sold) / Revenue
=(3.373 - 0.653) / 3.373
=80.64 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Cost of Goods Sold is also directly linked to another concept called Inventory Turnover:

Dova Pharmaceuticals's Inventory Turnover for the three months ended in Sep. 2019 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher inventory turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate inventory turnover. An average inventory is a better indication.


Dova Pharmaceuticals Cost of Goods Sold Related Terms

Thank you for viewing the detailed overview of Dova Pharmaceuticals's Cost of Goods Sold provided by GuruFocus.com. Please click on the following links to see related term pages.


Dova Pharmaceuticals (Dova Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
240 Leigh Farm Road, Suite 245, Durham, NC, USA, 27707
Dova Pharmaceuticals Inc is a United States based clinical-stage pharmaceutical company engaged in developing treatments for patients suffering from orphan diseases. It is focused on acquiring, developing and commercializing drug candidates for diseases that are treated by specialist physicians, with an initial focus on addressing thrombocytopenia, a disorder characterized by a low blood platelet count. The company's drug candidate, avatrombopag, is an orally administered thrombopoietin receptor agonist, or TPO-RA, that it is developing for the treatment of thrombocytopenia. The company's drug candidate, avatrombopag, is designed to mimic the effects of thrombopoietin, in vitro and in vivo. Thrombopoietin is a hormone produced in the liver and kidney that binds to its receptor.
Executives
Nancy Wysenski director 2200 SUNBURST STREET, CHATSWORTH CA 90401
Joseph Edelman 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Allen Lee F Md Phd officer: Chief Medical Officer C/O AMAG PHARMACEUTICALS, INC., 125 CAMBRIDGEPARK DRIVE, 6TH FLOOR, CAMBRIDGE MA 02140
Roger Jeffs director
Alfred J Novak director 325 NE 6TH ST, BOCA RATON FL 33432
David Zaccardelli director, officer: President & CEO 300 TRI STATE INTERNATIONAL, SUITE 272, LINCOLNSHIRE IL 60069
Paul B Manning director, 10 percent owner 200 GARRETT STREET SUITE S, CHARLOTTESVILLE VA 22902
Stalfort John A Iii director C/O ACUMEN PHARMACEUTICALS, INC., 427 PARK STREET, CHARLOTTESVILLE VA 22902
Jason Hoitt officer: Chief Commercial Officer C/O DOVA PHARMACEUTICALS, INC., 240 LEIGH FARM ROAD, SUITE 245, DURHAM NC 27707
Alex Sapir director, officer: President & CEO C/O DOVA PHARMACEUTICALS, INC., 240 LEIGH FARM ROAD, SUITE 245, DURHAM NC 27707

Dova Pharmaceuticals (Dova Pharmaceuticals) Headlines

From GuruFocus